Volume 3 of Advances in Medicinal Chemistry is comprised of four chapters on diverse aspects of medicinal chemistry. Chapter 1 presents an account of a research program which was started to discover a novel antipsychotic agent with minimal side effects for the treatment, principally, of schizophrenia. Chapter 2 relates an account on the discovery of novel antithrombotic drugs based on the RGD motif through a rational design approach. Chapter 3 presents the medicinal chemistry and preclinical development surrounding sertraline, a very important serotonin reuptake drug for the treatment of endogenous depression. Finally, Chapter 4 gives a summary of a series of boronic acid-based immunosuppressants that operate via inhibition of dipeptidypeptidase IV.
List of Contributors.
Preface (B.E. Maryanoff and C.A. Maryanoff).
- Novel Antipsychotics with Unique D2/5-HT1A Affinity and Minimal Extrapyramidal Side Effect Liability (A.B. Reitz and M.K. Scott).
- Antiplatelet and Antithrombotic Agents: from Viper Venom Proteins, to Peptides and Peptidomimetics, to Small Organic Molecules (P.L. Barker and R.R. Webb, II).
- Discovery and Preclinical Development of the Serotonin Reuptake Inhibitor Sertraline (W.M. Welch).
- Boronic Acid Inhibitors of Dipeptidyl Peptidase IV: A New Class of Immunosuppressive Agents (R.J. Snow and W.W. Bachovchin).
- © Elsevier Science 1995
- 4th January 1996
- Elsevier Science
- eBook ISBN:
- Hardcover ISBN:
@qu:REVIEW: "In summary, the third volume of this series continues to offer well written, interesting accounts of topics important to the discipline of medicinal chemistry and with up-to-date references. Some of the chapters seem well suited as special topics in graduate courses. This series should appeal to a broad audience of researchers, teachers, and students". @source:Journal of American Chemical Society